Daniel L. Gustafson

8.5k total citations
211 papers, 6.4k citations indexed

About

Daniel L. Gustafson is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel L. Gustafson has authored 211 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 52 papers in Oncology and 50 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel L. Gustafson's work include Veterinary Oncology Research (26 papers), Virus-based gene therapy research (19 papers) and Cancer Treatment and Pharmacology (17 papers). Daniel L. Gustafson is often cited by papers focused on Veterinary Oncology Research (26 papers), Virus-based gene therapy research (19 papers) and Cancer Treatment and Pharmacology (17 papers). Daniel L. Gustafson collaborates with scholars based in United States, Canada and Australia. Daniel L. Gustafson's co-authors include Douglas H. Thamm, Andrew Thorburn, Chris A. Pritsos, David Ross, Michael E. Long, David Siegel, Joseph A. Zirrolli, Ryan J. Hansen, Donna L. Dehn and Jin Yi Han and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Daniel L. Gustafson

205 papers receiving 6.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel L. Gustafson United States	45	2.9k	1.5k	1.3k	790	708	211	6.4k
Marián Hajdúch Czechia	51	5.6k 2.0×	880 0.6×	1.6k 1.2×	1.5k 1.8×	559 0.8×	422	10.7k
William DeGraff United States	45	4.7k 1.7×	917 0.6×	1.7k 1.3×	1.4k 1.7×	354 0.5×	100	10.9k
Peng Cao China	49	4.4k 1.5×	754 0.5×	872 0.7×	946 1.2×	432 0.6×	401	9.1k
Hiroshi Seno Japan	44	2.6k 0.9×	710 0.5×	2.1k 1.6×	785 1.0×	769 1.1×	398	8.2k
Saijun Fan China	50	4.7k 1.6×	939 0.6×	1.7k 1.3×	1.0k 1.3×	423 0.6×	173	8.6k
Shazib Pervaiz Singapore	58	5.9k 2.1×	600 0.4×	1.3k 1.0×	1.5k 1.9×	1.0k 1.4×	176	9.9k
Yong J. Lee United States	57	6.6k 2.3×	931 0.6×	1.6k 1.3×	1.7k 2.1×	758 1.1×	253	10.6k
Jian Jian Li United States	55	5.4k 1.9×	1.0k 0.7×	2.3k 1.8×	2.1k 2.7×	536 0.8×	196	9.5k
Li Li China	48	4.7k 1.6×	1.5k 1.0×	2.1k 1.6×	1.4k 1.8×	1.2k 1.7×	420	9.9k
Frederick E. Domann United States	53	5.0k 1.7×	661 0.4×	1.1k 0.9×	1.6k 2.0×	356 0.5×	162	7.8k

Countries citing papers authored by Daniel L. Gustafson

Since Specialization

Citations

This map shows the geographic impact of Daniel L. Gustafson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Gustafson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Gustafson more than expected).

Fields of papers citing papers by Daniel L. Gustafson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Gustafson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Gustafson. The network helps show where Daniel L. Gustafson may publish in the future.

Co-authorship network of co-authors of Daniel L. Gustafson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Gustafson. A scholar is included among the top collaborators of Daniel L. Gustafson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Gustafson. Daniel L. Gustafson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gustafson, Daniel L., et al.. (2025). Bioavailability of Oral Ondansetron in Dogs: A Crossover Study. Journal of Veterinary Pharmacology and Therapeutics. 49(1). 17–21.

Gustafson, Daniel L., et al.. (2023). Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine. 37(6). 2402–2409. 3 indexed citations

Alvarenga, Isabella Corsato, et al.. (2023). The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study. Journal of Veterinary Internal Medicine. 37(6). 2291–2300. 15 indexed citations

Ramirez, Dominique, et al.. (2023). Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue‐specific drug binding, transport, and metabolism. Pharmacology Research & Perspectives. 11(1). e01052–e01052. 7 indexed citations

Prigaro, Brett J., Hector Esquer, Qiong Zhou, et al.. (2022). Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. Journal of Medicinal Chemistry. 65(5). 3943–3961. 11 indexed citations

Gustafson, Daniel L., et al.. (2022). Pharmacokinetics, Safety, and Synovial Fluid Concentrations of Single- and Multiple-Dose Oral Administration of 1 and 3 mg/kg Cannabidiol in Horses. Journal of Equine Veterinary Science. 113. 103933–103933. 21 indexed citations

Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2021). A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical Cancer Research. 27(9). 2435–2441. 58 indexed citations

Regan, Daniel P., Lyndah Chow, Sunetra Das, et al.. (2021). Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. Clinical Cancer Research. 28(4). 662–676. 50 indexed citations

Zhou, Qiong, Hector Esquer, Laura A. Pike, et al.. (2020). First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Molecular Cancer Therapeutics. 19(8). 1598–1612. 23 indexed citations

10.

Das, Sunetra, et al.. (2019). Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing. Molecular Cancer Therapeutics. 18(8). 1460–1471. 23 indexed citations

11.

Gustafson, Daniel L., et al.. (2018). Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. Journal of Pharmacology and Experimental Therapeutics. 365(3). 447–459. 64 indexed citations

12.

Morrow, James J., Arnulfo Mendoza, Allyson E. Koyen, et al.. (2016). mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo. Clinical Cancer Research. 22(24). 6129–6141. 22 indexed citations

13.

Gustafson, Daniel L., Jared S. Fowles, Kristen C. Brown, & Dan Theodorescu. (2015). Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. Assay and Drug Development Technologies. 13(10). 623–627. 4 indexed citations

14.

Maycotte, Paola, Christy M. Gearheart, Rebecca Barnard, et al.. (2014). STAT3-Mediated Autophagy Dependence Identifies Subtypes of Breast Cancer Where Autophagy Inhibition Can Be Efficacious. Cancer Research. 74(9). 2579–2590. 152 indexed citations

15.

Spreafico, Anna, John J. Tentler, Todd M. Pitts, et al.. (2013). Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. Clinical Cancer Research. 19(15). 4149–4162. 58 indexed citations

16.

Ellis, Bonnie K., Jack A. Stanford, Daniel Goodman, et al.. (2011). Long-term effects of a trophic cascade in a large lake ecosystem. Proceedings of the National Academy of Sciences. 108(3). 1070–1075. 163 indexed citations

17.

Diamond, Jennifer R., Bruno R. Bastos, Ryan J. Hansen, et al.. (2010). Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(4). 849–860. 57 indexed citations

18.

Bradshaw‐Pierce, Erica L., et al.. (2008). Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Molecular Cancer Therapeutics. 7(9). 3006–3017. 14 indexed citations

19.

Selting, Kim A., J. Clifford Waldrep, Carol R. Reinero, et al.. (2008). Feasibility and Safety of Targeted Cisplatin Delivery to a Select Lung Lobe in Dogs via the AeroProbe ^® Intracorporeal Nebulization Catheter. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 21(3). 255–268. 34 indexed citations

20.

Gustafson, Daniel L., et al.. (2005). P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Cancer Chemotherapy and Pharmacology. 56(3). 248–254. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact